Document:

Amendment No. 2 to Sodium Gamma Hydroxybutyrate Development and Supply Agreement

 Exhibit 10.54 
 Amendment No.2 
 to 
 Sodium Gamma Hydroxybutyrate 
 Development and Supply Agreement 
 This Amendment No.2 (the “Amendment”) to the Sodium Gamma Hydroxybutyrate Development and Supply Agreement dated November 6, 1996, as amended, is entered
into as of March 30, 2007 (the “Execution Date”) between Jazz Pharmaceuticals, Inc., a Delaware corporation (“Jazz Pharmaceuticals”) and Lonza, Inc., a New York corporation (“Supplier”). 
 RECITALS 
 WHEREAS, Supplier and Orphan
Medical, Inc., a Delaware corporation (“Orphan Medical”), have previously executed the Sodium Gamma Hydroxybutyrate Development and Supply Agreement dated as of November 6, 1996, as amended by Amendment No. 1 dated
February 7, 2005 (collectively, the “Agreement”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement; 
 WHEREAS, pursuant to Section 18.5 of the Agreement, Orphan Medical assigned its rights and obligations under the Agreement to Jazz Pharmaceuticals and all references to “Orphan Medical” in the Agreement
therefore have been replaced by “Jazz Pharmaceuticals”; and 
 WHEREAS, in accordance with Section 18.4 of the Agreement, the
parties wish to amend the Agreement as set forth in this Amendment. 
 NOW THEREFORE, in consideration of the mutual agreements and covenants
set forth hereinafter and in the Agreement and other good and valuable consideration, receipt of which is hereby acknowledged, Jazz Pharmaceuticals and Supplier hereby agree as follows: 
  

	 	1.	Amendment of the Definitions. Jazz Pharmaceuticals and Supplier hereby amend Article 1 of the Agreement as follows: 

  

	 	1.1	The definition of “Contract Year” set forth in Section 1.3 is amended and restated in its entirety to read as follows: 

 “1.3 “Contract Year” means each twelve (12) month period during the term of
this Agreement starting on January 1st and ending on December 31st.” 
  

	 	1.2	A new definition of “Quota” is hereby added to Article 1 as follows: 

 “1.25 “Quota” means the manufacturing quota quantity of the Drug allotted by the DEA to Supplier in a Contract Year in order for Supplier to perform the services hereunder.” 

	 	2.	Section 5.5 and 5.6 remain as stated in the Sodium Gamma Hydroxybutyrate Development and Supply Agreement dated as of November 6, 1996 

  

	 	3.	Amendment of Forecasts, Orders and Deliveries. Jazz Pharmaceuticals and Supplier hereby amend and restate Section 6.1 of the Agreement in its entirety as follows:

 “6.1 No later than the tenth (10th) calendar day of each calendar month during the term of the Agreement, Jazz Pharmaceuticals shall furnish to Supplier a
written rolling twelve (12) month forecast of Jazz Pharmaceuticals’ anticipated purchases, including shipment dates, of the Drug (the “Forecast”). The first three (3) months covered in each twelve (12) month Forecast
provided shall constitute a firm order (each, a “Firm Order”); the remaining nine (9) months covered by each Forecast shall be a non-binding estimate only. Each Forecast shall cover a twelve (12)-month forecast period starting the
first (1st) day of the calendar month that is three (3) months after the month in which Jazz Pharmaceuticals provided such Forecast to Supplier. By way of example, the Forecast which Jazz Pharmaceuticals provides by April 10, 2007
shall cover the period from July 1, 2007 until October 30, 2008. For amounts of the Drug set forth in the Forecast, Jazz Pharmaceuticals and Supplier realize that the Quota may restrict manufacturing and hence delivery of shipments
throughout the calendar year for which such Quota applies. If the Quota restricts, and is anticipated to restrict, Supplier’s ability to meet the manufacturing requirements set forth in the Forecast, Supplier will promptly notify Jazz
Pharmaceuticals and the parties will meet and agree on a plan to resolve the anticipated shortfall in requested Drug within 30 days. 
 (a) To ensure an uninterrupted supply of the Drug and to mitigate manufacturing delays caused by the Quota, Supplier agrees to use its commercially reasonable efforts to manufacture and maintain a reserve of Drug (the “Target
Reserve”) for purchase by Jazz Pharmaceuticals based upon the Quota in such calendar year. The Target Reserve for any calendar year shall be calculated as follows: 
  

			
	 Quota
	  	Target Reserve
	 Less than 15 mT
	  	2 mT
	 15 to 30 mT
	  	4 mT
	 Greater than 30 mT
	  	6 mT

  

 2 

 The inventory must be moved every calendar year, if at any time, the manufacture date of the stock in
inventory is greater than one (1) calendar year from the date is was released; which could equate to a portion of the inventory, Jazz Pharmaceuticals agrees to compensate Supplier for the inventory on stock if otherwise not consumed.

 Notwithstanding the above, the parties acknowledge that the DEA has ultimate control of the amount of the Drug that can be produced each
calendar year. 
 (b) Supplier agrees to use its commercially reasonable efforts to obtain from the DEA the manufacturing
quota of the Drug requested by Jazz Pharmaceuticals in a Contract Year including, but not limited to, any additional manufacturing quota amounts of the Drug that Jazz Pharmaceuticals may request Supplier to obtain during the Contract Year.

 (c) Supplier acknowledges that in connection with seeking additional manufacturing quota of the Drug from the DEA pursuant
to Section 6.1(b) above, Jazz Pharmaceuticals may wish to reserve capacity in addition to the capacity required to manufacture the Forecast. Accordingly, Jazz Pharmaceuticals will notify Supplier at least ninety (90) days in advance if it
wishes to reserve additional capacity to manufacture additional Drug that is subject to the approval of the DEA of additional manufacturing quota of the Drug. If the reserve capacity is not needed because of quota restrictions or other, Jazz
Pharmaceuticals will pay Supplier the equipment changeover fee of $150,000 and fixed costs ($19/kg). If the reserve capacity is needed in a quota restricted situation, but the expected campaign is smaller than indicated, Jazz Pharmaceuticals will
pay the price/gram indicative of the actual campaign. In either case, Supplier may accept other opportunities to use its production capacity; however, the fees could be waived or, if paid, then Jazz Pharmaceuticals will be credited against future
Firm Orders if Supplier can fill the equipment with other projects. 
 (d) Supplier shall provide or purchase all materials
and supplies necessary to manufacture the Drug. Supplier shall 

  

 3 

 
manufacture the Drug in accordance with the Specifications, the Validation Protocol and applicable cGMPs and shall package, label and/or otherwise prepare
the Drug for bulk delivery to a Jazz Pharmaceuticals designated drug product manufacturer. Supplier further agrees that the Drug shall meet FDA, European, and Canadian standards and specifications. The International Conference on Harmonization (ICH)
guidelines will be followed for development and manufacturing decisions.” 
  

	 	4.	Amendment to Choice of Law. Jazz Pharmaceuticals and Supplier hereby amend and restate Section 18.1 of the Agreement in its entirety as follows:

 “18.1 Choice of Law. This Agreement shall be governed by and interpreted in accordance with the laws of New York,
without regard to its conflict of laws provisions.” 
  

	 	5.	Amendment to Notices. Jazz Pharmaceuticals and Supplier hereby amend Section 18.2 of the Agreement to replace the address set forth for Jazz Pharmaceuticals set forth in
Section 18.2 with the following addresses: 

  

			
	“If to Jazz Pharmaceuticals:	  	Jazz Pharmaceuticals, Inc.
		  	3180 Porter Drive
		  	Palo Alto, California 94304
		  	Attn: Director of Manufacturing
		  	Fax: (650) 496-2641
		
	with a copy to:	  	Jazz Pharmaceuticals, Inc.
		  	3180 Porter Drive
		  	Palo Alto, California 94304
		  	Attn: General Counsel
		  	Fax: (650) 496-3781”

 Amendment of Appendix H. Appendix H of the Agreement is hereby deleted in its entirety and
hereby replaced with the following, which is attached hereto as Exhibit A. Pricing is for 2007. However, Supplier will use its commercially reasonable efforts to make improvements to the manufacturing process which would result in
reduced costs and thus reduced pricing to Jazz Pharmaceuticals. 
  

	 	 6.
	 Acknowledgement of Contract Year. Jazz Pharmaceuticals and Supplier acknowledge and agree that the Contract Year
that commenced on August 1, 2006 under the Agreement shall continue until December 31, 2007 and thereafter each Contract Year shall commence on January 1st and end on December 31st. 

  

	 	7.	No Other Changes. Except as provided in this Amendment, the Agreement remains in full force and effect as originally executed. 

  

 4 

	 	8.	Headings. Headings in this Amendment are for convenience of reference only and shall not be considered in construing this Amendment. 

  

	 	9.	Severability. If any provision of this Amendment is held unenforceable by a court or tribunal of competent jurisdiction because it is invalid or conflicts with any law of any
relevant jurisdiction, the validity of the remaining provisions shall not be affected. In such event, the parties shall negotiate a substitute provision that, to the extent possible, accomplishes the original business purpose.

  

	 	10.	Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same
instrument. Signatures provided by facsimile transmission shall be deemed to be original signatures. 

 IN WITNESS WHEREOF, the
parties have executed this Amendment No.2 as of the Execution Date. 
  

											
	 Jazz Pharmaceuticals, Inc.
	 		 	Lonza, Inc.	 	
						
	By:	 	 /s/ Carol A. Gamble
	 		 	By:	 	 /s/ Vincent DiVito
	 	
	Its:	 	Senior V.P. & General Counsel	 		 	Its:	 	VP and Chief Financial Officer	 	
		 		 		 		 		 	

  

 5 

 Exhibit A 
 Appendix H 
 Revised Drug Price 
 2007 Price: Below is the annual price or campaign price. The DEA quota granted at the end of each calendar year will define the annual price for the following year in the below table. If Jazz Pharmaceuticals and Lonza
have quota restrictions and all orders can not be met then subsequent pricing will be dictated by campaign size below agreed to in writing by Jazz Pharmaceuticals and Lonza. 
  

				
	 Campaign Size or Annual Price (MT) SXB Salt
	  	Price (USD)
	 	  	per/campaign
	 2
	  	$	130
	 3
	  	$	120
	 4
	  	$	105
	 5
	  	$	95
	 6
	  	$	92
	 7
	  	$	90
		
	 8
	  	$	85
	 9
	  	$	83
	 10
	  	$	82.5
	 11
	  	$	81
	 12 to 20
	  	$	78
	 20+
	  	$	72

 Assumptions: 
  

	 	•	 	 The lower number is the minimum manufactured in a single campaign for each price section 

  

	 	•	 	 Vessel size 750 gallon 

  

	 	•	 	 Cycle time 46-73 hours or less (including drying) 

  

	 	•	 	 Material purchased within 30 days of release 

  

	 	•	 	 Yield >/= 472.9 kg SXB/batch 

 This price
includes: 
  

	 	•	 	 All raw materials, processing, depreciation, overheads, profit, packaging. 

  

	 	•	 	 Scale up from intermediate size reactors to 1500 gallon or larger vessels (if needed). 

  

	 	•	 	 DMF (or equivalent) modifications required 

  

	 	•	 	 Reasonable regulatory support to Jazz 

  

	 	•	 	 Ongoing process improvement efforts with benefit sharing with Jazz 

  

 6 

 Note: 
  

	 	•	 	 Lonza and Jazz agree that any campaign that would come UNDER 8 metric tons will trigger a discussion on how to plan the most beneficial campaign program. The second
pricing schedule (shown below) will be used when improvements are made to the process. 

 Example of Price Targets based on improvements
that need to be discussed with Jazz: 
  

				
	 Annual or Campaign Size (MT)
	  	Pricing ($USD)
	 2 to 5
	  	$	110
	 5 to 8
	  	$	85
	 8 to 12
	  	$	75
	 12 to 20
	  	$	65
	 20+
	  	$	60

  

 71996 Employee Stock Purchase Plan, as amended

 Exhibit 10.1 
 TERADYNE, INC. 
 1996 EMPLOYEE STOCK PURCHASE PLAN 
 (as amended as of May 24, 2007) 
 Article
1—Purpose. 
 This 1996 Employee Stock Purchase Plan (the “Plan”) is intended to encourage stock ownership by all
eligible employees of Teradyne, Inc. (the “Company”), a Massachusetts corporation, and its participating subsidiaries (as defined in Article 17) so that they may share in the growth of the Company by acquiring or increasing their
proprietary interest in the Company. The Plan is designed to encourage eligible employees to remain in the employ of the Company and its participating subsidiaries. The Plan is intended to constitute an “employee stock purchase plan”
within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Code”). 
 Article
2—Administration of the Plan. 
 The Plan may be administered by a committee appointed by the Board of Directors of the Company
(the “Committee”). The Committee shall consist of not less than two members of the Company’s Board of Directors. The Board of Directors may from time to time remove members from, or add members to, the Committee. Vacancies on the
Committee, howsoever caused, shall be filled by the Board of Directors. The Committee may select one of its members as Chairman, and shall hold meetings at such times and places as it may determine. Acts by a majority of the Committee, or acts
reduced to or approved in writing by a majority of the members of the Committee, shall be the valid acts of the Committee. 
 The
interpretation and construction by the Committee of any provisions of the Plan or of any option granted under it shall be final, unless otherwise determined by the Board of Directors. The Committee may from time to time adopt such rules and
regulations for carrying out the Plan as it may deem best, provided that any such rules and regulations shall be applied on a uniform basis to all employees under the Plan. No member of the Board of Directors or the Committee shall be liable for any
action or determination made in good faith with respect to the Plan or any option granted under it. 
 In the event the Board of Directors
fails to appoint or refrains from appointing a Committee, the Board of Directors shall have all power and authority to administer the Plan. In such event, the word “Committee” wherever used herein shall be deemed to mean the Board of
Directors. 
 Article 3—Eligible Employees. 
 No option may be granted to any person serving as a member of the Committee at the time of grant. Subject to the foregoing limitation, all employees of the Company or any of its participating subsidiaries on United
States payroll who are employees of the Company or any of its participating subsidiaries on or before the first day of any Payment Period (as defined in Article 5), and whose customary employment is not less than twenty hours per week and more
than five months in any calendar year shall be eligible to receive options under the Plan to purchase common stock of the Company, par value $.125 per share (“Common Stock”). All eligible employees shall have the same rights and
privileges hereunder. Persons who elect to enter the Plan in accordance with Article 7 and who are eligible employees on the first business day of any Payment Period (as defined in Article 5) shall receive their options as of such day.
Persons who elect to enter the Plan in accordance with Article 7 and who become eligible employees after any date on which options are granted under the Plan shall be granted options on the first business day of the next succeeding Payment
Period on which options are granted to eligible employees under the Plan. In no event, however, may an employee be granted an option if such employee, immediately after the option was granted, would be treated as owning stock possessing
five percent or more 

 
of the total combined voting power or value of all classes of stock of the Company or of any parent corporation or subsidiary corporation, as the terms
“parent corporation” and “subsidiary corporation” are defined in Section 424(e) and (f) of the Code. For purposes of determining stock ownership under this paragraph, the rules of Section 424(d) of the Code shall
apply, and stock which the employee may purchase under outstanding options shall be treated as stock owned by the employee. 
 Article 4—Stock Subject to the Plan. 
 The stock subject to the options under the Plan shall be authorized
but unissued Common Stock, or shares of Common Stock reacquired by the Company, including shares purchased in the open market. The aggregate number of shares which may be issued pursuant to the Plan is 20,400,000, subject to adjustment as provided
in Article 12. If any option granted under the Plan shall expire or terminate for any reason without having been exercised in full or shall cease for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto shall
again be available under the Plan. 
 Article 5—Payment Periods and Stock Options. 
 For the duration of the Plan, a Payment Period shall be defined as each six-month period commencing on the first day of January and ending on the last day
of June and commencing on the first day of July and ending on the last day of December of each calendar year. Notwithstanding the foregoing, the first Payment Period during which payroll deductions will be accumulated under the Plan shall commence
on July 1, 1996 and shall end on December 31, 1996. 
 On the first business day of each Payment Period, the Company will grant to
each eligible employee who is then a participant in the Plan an option to purchase on the last day of such Payment Period, at the Option Price hereinafter provided for, a maximum number of shares (limited in accordance with this Article 5 and
Article 8) on condition that such employee remains eligible to participate in the Plan throughout the remainder of such Payment Period. The participant shall be entitled to exercise the option so granted only to the extent of the participant’s
accumulated payroll deductions on the last day of such Payment Period. The Option Price per share for each Payment Period shall be the lesser of (i) 85% of the fair market value of the Common Stock on the first business day of the Payment
Period and (ii) 85% of the fair market value of the Common Stock on the last business day of the Payment Period, in either event rounded up to the nearest cent. The foregoing limitation on the number of shares subject to option and the Option
Price shall be subject to adjustment as provided in Article 12. 
 For purposes of the Plan, the term “fair market value” on
any date means (i) the closing price (on that date) of the Common Stock on the principal national securities exchange on which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (ii) the
average of the closing bid and asked prices last quoted (on that date) by an established quotation service for over-the-counter securities, if the Common Stock is not reported on a national securities exchange; or (iii) if the Common Stock is
not publicly traded, the fair market value of the Common Stock as determined by the Committee after taking into consideration all factors which it deems appropriate, including, without limitation, recent sale and offer prices of the Common Stock in
private transactions negotiated at arm’s length. 
 For purposes of the Plan, the term “business day” means a day on which
there is trading on The Nasdaq Stock Market or the aforementioned national securities exchange, whichever is applicable pursuant to the preceding paragraph; and if neither is applicable, a day that is not a Saturday, Sunday or legal holiday in
Massachusetts. 
 Notwithstanding any other provision herein, no employee shall be granted an option which permits the employee’s right
to purchase stock under the Plan, and under all other Section 423(b) employee stock purchase plans of the Company and any parent or subsidiary corporations, to accrue at a rate which exceeds $25,000 of fair market value of such stock
(determined on the date or dates that options on such stock were granted) for each calendar year in which such option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the
Code. If the 

 
participant’s accumulated payroll deductions on the last day of the Payment Period would otherwise enable the participant to purchase Common Stock in
excess of the Section 423(b)(8) $25,000 limitation described in this paragraph, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of the shares actually purchased shall be promptly refunded to the
participant by the Company, without interest. 
 Article 6—Exercise of Option. 
 Each eligible employee who continues to be a participant in the Plan on the last day of a Payment Period shall be deemed to have exercised his or her
option on such date and shall be deemed to have purchased from the Company such number of full shares of Common Stock reserved for the purpose of the Plan as the participant’s accumulated payroll deductions on such date will pay for at the
Option Price, subject to the Section 423(b)(8) $25,000 limitation described in Article 5. If the individual is not a participant on the last day of a Payment Period, then he or she shall not be entitled to exercise his or her option. Only
full shares of Common Stock may be purchased under the Plan. Unused payroll deductions remaining in a participant’s account at the end of a Payment Period solely by reason of the inability to purchase a fractional share (and for no other
reason) shall be refunded. 
 Article 7—Authorization for Entering the Plan. 
 An employee may elect to enter the Plan by filling out, signing and delivering to the Company an authorization: 
 A. Stating the percentage to be deducted from the employee’s pay; 
 B. Authorizing the purchase of stock for the employee in each Payment Period in accordance with the terms of the Plan; and 
 C. Specifying the exact name or names in which stock purchased for the employee is to be issued as provided under Article 11 hereof.

 Such authorization must be received by the Company on or before the first day of the next succeeding Payment Period. 
 Unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on
file under the Plan will continue from one Payment Period to succeeding Payment Periods as long as the Plan remains in effect. 
 The Company
will accumulate and hold for each participant’s account the amounts deducted from his or her pay. No interest will be paid on these amounts. 
 Article 8—Maximum Amount of Payroll Deductions. 
 An employee may authorize payroll deductions in an amount
(expressed as a whole percentage) not less than two percent (2%) but not more than ten percent (10%) of the employee’s cash compensation. 
 Article 9—Change in Payroll Deductions. 
 Deductions may not be increased during a Payment Period.
Deductions may be decreased during a Payment Period, provided that an employee may not decrease his deduction more than once during any Payment Period. 
 Article 10—Withdrawal from the Plan. 
 A participant may withdraw from the Plan (in whole but not in part)
at any time prior to the last day of a Payment Period by delivering a withdrawal notice to the Company. 
  

 To re-enter the Plan, an employee who has previously withdrawn must file a new authorization on or before
the first day of the next Payment Period in which he or she wishes to participate. The employee’s re-entry into the Plan becomes effective at the beginning of such Payment Period, provided that he or she is an eligible employee on the first
business day of the Payment Period. 
 Article 11—Issuance of Stock. 
 Certificates for stock issued to participants shall be delivered as soon as practicable after each Payment Period by the Company’s transfer agent.

 Stock purchased under the Plan shall be issued only in the name of the participant, or if the participant’s authorization so
specifies, in the name of the participant and another person of legal age as joint tenants with rights of survivorship. 
 Article 12—Adjustments. 
 Upon the happening of any of the following described events, a participant’s
rights under options granted under the Plan shall be adjusted as hereinafter provided: 
 A. In the event that the shares of
Common Stock shall be subdivided or combined into a greater or smaller number of shares or if, upon a reorganization, split-up, liquidation, recapitalization or the like of the Company, the shares of Common Stock shall be exchanged for other
securities of the Company, each participant shall be entitled, subject to the conditions herein stated, to purchase such number of shares of Common Stock or amount of other securities of the Company as were exchangeable for the number of shares of
Common Stock that such participant would have been entitled to purchase except for such action, and appropriate adjustments shall be made in the purchase price per share to reflect such subdivision, combination or exchange; and 
 B. In the event the Company shall issue any of its shares as a stock dividend upon or with respect to the shares of stock of the class
which shall at the time be subject to options hereunder, each participant upon exercising such an option shall be entitled to receive (for the purchase price paid upon such exercise) the shares as to which the participant is exercising his or her
option and, in addition thereto (at no additional cost), such number of shares of the class or classes in which such stock dividend or dividends were declared or paid, and such amount of cash in lieu of fractional shares, as is equal to the number
of shares thereof and the amount of cash in lieu of fractional shares, respectively, which the participant would have received if the participant had been the holder of the shares as to which the participant is exercising his or her option at all
times between the date of the granting of such option and the date of its exercise. 
 Upon the happening of any of the foregoing events, the
class and aggregate number of shares set forth in Article 4 hereof which are subject to options which have been or may be granted under the Plan and the limitations set forth in the second paragraph of Article 5 shall also be appropriately
adjusted to reflect the events specified in paragraphs A and B above. Notwithstanding the foregoing, any adjustments made pursuant to paragraphs A or B shall be made only after the Committee, based on advice of counsel for the Company,
determines whether such adjustments would constitute a “modification” (as that term is defined in Section 424 of the Code). If the Committee determines that such adjustments would constitute a modification, it may refrain from making
such adjustments. 
 If the Company is to be consolidated with or acquired by another entity in a merger, a sale of all or substantially all
of the Company’s assets or otherwise (an “Acquisition”), the Committee or the board of directors of any entity assuming the obligations of the Company hereunder (the “Successor Board”) shall, with respect to options then
outstanding under the Plan, either (i) make appropriate provision for the continuation of such options by arranging for the substitution on an equitable basis for the shares then subject to such options either (a) the consideration payable
with respect to the outstanding shares of the Common Stock in connection with the Acquisition, (b) shares of stock of the successor corporation, or a 

 
parent or subsidiary of such corporation, or (c) such other securities as the Successor Board deems appropriate, the fair market value of which shall
not exceed the fair market value of the shares of Common Stock subject to such options immediately preceding the Acquisition; or (ii) terminate each participant’s options in exchange for a cash payment equal to the excess of the fair
market value on the date of the Acquisition of the number of shares of Common Stock that the participant’s accumulated payroll deductions as of the date of the Acquisition could purchase, at an option price determined with reference only to the
first business day of the applicable Payment Period and subject to Code Section 423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase over the aggregate option price to such participant
thereof. 
 The Committee or Successor Board shall determine the adjustments to be made under this Article 12, and its determination
shall be conclusive. 
 Article 13—No Transfer or Assignment of Employee’s Rights. 
 An option granted under the Plan may not be transferred or assigned, otherwise than by will or by the laws of descent and distribution. Any option granted
under the Plan may be exercised, during the participant’s lifetime, only by the participant. 
 Article 14—Termination of
Employee’s Rights. 
 Whenever a participant ceases to be an eligible employee because of retirement, voluntary or involuntary
termination, resignation, layoff, discharge, death or for any other reason, his or her rights under the Plan shall immediately terminate, and the Company shall promptly refund, without interest, the entire balance of his or her payroll deduction
account under the Plan; provided, however, that if an employee is laid off during the last three months of any Payment Period, he shall nevertheless be deemed to be a participant in the Plan on the last day of the Payment Period.
Notwithstanding the foregoing, eligible employment shall be treated as continuing intact while a participant is on military leave, sick leave or other bona fide leave of absence, for up to 90 days, or, if such leave is longer than 90 days, for
so long as the participant’s right to re-employment is guaranteed either by statute or by written contract. Notwithstanding any other provision herein, if a participant’s employment is terminated by reason of retirement, and the date of
such termination occurs after the date that is 3 months prior to the last day of the Payment Period, such participant’s rights under the Plan are not immediately terminated, and if the participant has not withdrawn from the Plan, such
participant’s options shall be deemed to have been exercised on the last day of the Payment Period in accordance with the terms of the Plan. 
 Article 15—Termination and Amendments to Plan. 
 The Plan may be terminated at any time by the
Company’s Board of Directors but such termination shall not affect options then outstanding under the Plan. If at any time shares of stock reserved for the purpose of the Plan remain available for purchase but not in sufficient number to
satisfy all then unfilled purchase requirements, the available shares shall be apportioned among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase stock,
and the Plan shall terminate. Upon such termination or any other termination of the Plan, all payroll deductions not used to purchase stock will be refunded, without interest. 
 The Committee or the Board of Directors may from time to time adopt amendments to the Plan provided that, without the approval of the shareholders of the
Company, no amendment may (i) increase the number of shares that may be issued under the Plan; (ii) change the class of employees eligible to receive options under the Plan, if such action would be treated as the adoption of a new plan for
purposes of Code Section 423(b) and the regulations thereunder; (iii) cause Rule 16b-3 under the Securities Exchange Act of 1934 to become inapplicable to the Plan or (iv) materially revise the Plan pursuant to the rules and
regulations of the NYSE. 

 Article 16—Limits on Sale of Stock Purchased under the Plan. 
 The Plan is intended to provide shares of Common Stock for investment and not for resale. The Company does not, however, intend to restrict or influence
any employee in the conduct of his or her own affairs. An employee may, therefore, sell stock purchased under the Plan at any time the employee chooses, subject to compliance with any applicable federal or state securities laws and subject to any
restrictions imposed under Article 21 to ensure that tax withholding obligations are satisfied. THE EMPLOYEE ASSUMES THE RISK OF ANY MARKET FLUCTUATIONS IN THE PRICE OF THE STOCK. 
 Article 17—Participating Subsidiaries. 
 The term “participating subsidiary” shall mean any present or future subsidiary of the Company, as that term is defined in Section 424(f) of the Code, that is designated from time to time by the Board of Directors to
participate in the Plan. The Board of Directors shall have the power to make such designation before or after the Plan is approved by the shareholders. 
 Article 18—Optionees Not Shareholders. 
 Neither the granting of an option to an employee nor the deductions
from his or her pay shall constitute such employee a stockholder of the shares covered by an option until such shares have been actually purchased by the employee. 
 Article 19—Application of Funds. 
 The proceeds received by the Company from the sale of Common Stock
pursuant to options granted under the Plan will be used for general corporate purposes. 
 Article 20—Notice to Company of Disqualifying
Disposition. 
 By electing to participate in the Plan, each participant agrees to notify the Company in writing immediately after the
participant transfers Common Stock acquired under the Plan, if such transfer occurs within two years after the first business day of the Payment Period in which such Common Stock was acquired. Each participant further agrees to provide any
information about such a transfer as may be requested by the Company or any subsidiary corporation in order to assist it in complying with the tax laws. Such dispositions generally are treated as “disqualifying dispositions” under Sections
421 and 424 of the Code, which have certain tax consequences to participants and to the Company and its participating subsidiaries. 
 Article 21—Withholding of Additional Income Taxes. 
 By electing to participate in the Plan, each
participant acknowledges that the Company and its participating subsidiaries are required to withhold taxes with respect to the amounts deducted from the participant’s compensation and accumulated for the benefit of the participant under the
Plan, and each participant agrees that the Company and its participating subsidiaries may deduct additional amounts from the participant’s compensation, when amounts are added to the participant’s account, used to purchase Common Stock or
refunded, in order to satisfy such withholding obligations. Each participant further acknowledges that when Common Stock is purchased under the Plan the Company and its participating subsidiaries may be required to withhold taxes with respect to all
or a portion of the difference between the fair market value of the Common Stock purchased and its purchase price, and each participant agrees that such taxes may be withheld from compensation otherwise payable to such participant. It is intended
that tax withholding will be accomplished in such a manner that the full amount of payroll deductions elected by the participant under Article 7 will be used to purchase Common Stock. However, if amounts sufficient to satisfy applicable tax
withholding obligations have not been withheld from compensation otherwise payable to any participant, then, notwithstanding any other provision of the Plan, the Company may withhold such taxes from the participant’s accumulated payroll
deductions and apply the net amount to the purchase of Common Stock, unless the participant pays to the Company, prior to the exercise date, an amount sufficient to satisfy such withholding obligations. Each participant further acknowledges that the

 
Company and its participating subsidiaries may be required to withhold taxes in connection with the disposition of stock acquired under the Plan and agrees
that the Company or any participating subsidiary may take whatever action it considers appropriate to satisfy such withholding requirements, including deducting from compensation otherwise payable to such participant an amount sufficient to satisfy
such withholding requirements or conditioning any disposition of Common Stock by the participant upon the payment to the Company or such subsidiary of an amount sufficient to satisfy such withholding requirements. 
 Article 22—Governmental Regulations. 
 The Company’s obligation to sell and deliver shares of Common Stock under the Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares. 
 Government regulations may impose reporting or other obligations on the Company with respect to the Plan. For example, the Company may be required to
identify shares of Common Stock issued under the Plan on its stock ownership records and send tax information statements to employees and former employees who transfer title to such shares. 
 Article 23—Governing Law. 
 The
validity and construction of the Plan shall be governed by the laws of Massachusetts, without giving effect to the principles of conflicts of law thereof. 
 Article 24—Approval of Board of Directors and Stockholders of the Company. 
 The Plan was adopted by the
Board of Directors on March 19, 1996 and on such date the Board of Directors resolved that the Plan was to be submitted to the shareholders of the Company for approval at the next meeting of shareholders. The plan was subsequently approved by
the shareholders.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]